Exhibit 99.4

EUPRAXIA PHARMACEUTICALS INC.

(the “Company”)

CERTIFICATE

TO:

British Columbia Securities Commission Alberta Securities Commission Financial and Consumer Affairs Authority of Saskatchewan Manitoba Securities Commission Ontario Securities Commission Financial and Consumer Services Commission (New Brunswick) Nova Scotia Securities Commission Office of the Superintendent of Securities Service Newfoundland & Labrador Prince Edward Island Office of the Superintendent of Securities

RE:

The abridgement of time pursuant to National Instrument 54-101 – Communication with Beneficial Owners of Securities of a Reporting Issuer (“NI 54-101”)

In connection with the abridgement of the time periods (the “Abridgement”) by the Company for notifying various regulatory authorities, exchanges and depositories of the record date and meeting date for the Company’s annual general and special meeting of shareholders to be held on June 6, 2024 (the “Meeting”), and for delivering requests for beneficial ownership information to certain participants and intermediaries in connection with the Meeting, the undersigned, Bruce Cousins, Chief Financial Officer of the Company, hereby certifies for and on behalf of the Company and not in his personal capacity as follows:

(a) the Company has made arrangements regarding the delivery of proxy-related materials in compliance with the applicable timing requirements in Sections 2.9 and 2.12 of NI 54-101;

(b) the Company has otherwise carried out all of the requirements of NI 54-101 in addition to those described in paragraph (a) above; and

(c) the Company is relying upon Section 2.20 of NI 54-101 in making the Abridgement with respect to subsections 2.2(1) and 2.5(1) of NI 54-101.

[Remainder of page left intentionally blank.]

DATED as of May 15, 2024.

EUPRAXIA PHARMACEUTICALS INC.
By:	/s/ Bruce Cousins
Name:	Bruce Cousins
Title:	Chief Financial Officer